Loading, Please Wait...
BEVERLY, Mass. and TORONTO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today reported that its Embryotech Laboratories Inc. subsidiary has added Good Laboratory Practice (GLP) for Non-Clinical Laboratory Studies to its ANSI National Accreditation Board (ANAB) certificate of accreditation. Embryotech also announces the addition of Human Sperm Motility Assay (SMA) utilizing Computer Assisted Sperm Analysis (CASA) software to their scope of accreditation during their reassessment of ISO 17025:2017.
Joel Lopez, Senior Vice President and General Manager of Embryotech, stated, “We have added GLP accreditation in response to customer demand for GLP studies to support their submissions to the FDA for 510K clearance and to other regulatory bodies, which has been a growing area of business for us. By adding these offerings to our comprehensive suite of quality control testing services, Embryotech cements its role as the leading testing services provider to the Assisted Reproductive Technologies field. We believe we are the only lab which is fully certified to do GLP studies with the full array of ISO 17025:2017 accredited tests that meet the needs of the ART field.”
Embryotech’s scope of accreditation includes testing of Raw Materials, Media, and Devices Intended for use in the Medical Industry, using the following tests or measurements:
Please visit our website for a full description of our products and services at www.embryotech.com.
About Hamilton Thorne Ltd. ( www.hamiltonthorne.ltd )
Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.
Neither the TSX Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict including the risk that the Company may not be able to obtain the necessary regulatory approvals, as applicable. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com
For more information, please contact:
|David Wolf, President & CEO
Hamilton Thorne Ltd.
|Michael Bruns, CFO
Hamilton Thorne Ltd.
Bristol Investor Relations